STOCK TITAN
  1. Home
  2. News
  3. GLYC

GlycoMimetics Inc - GLYC STOCK NEWS

Welcome to our dedicated news page for GlycoMimetics (Ticker: GLYC), a resource for investors and traders seeking the latest updates and insights on GlycoMimetics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect GlycoMimetics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of GlycoMimetics's position in the market.

News
GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023
Rhea-AI Summary
GlycoMimetics, Inc. (GLYC) reported positive results from the Phase 1a study of GMI-1687 for sickle cell disease. The company plans to submit a New Drug Application for uproleselan to the FDA by the end of 2024. Cash and cash equivalents as of December 31, 2023, were $41.8 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.58%
Tags
earnings
-
News
GlycoMimetics to Report Fourth Quarter and 2023 Full Year Financial Results on March 27, 2024
Rhea-AI Summary
GlycoMimetics, Inc. (Nasdaq: GLYC) will host a conference call and webcast to report Q4 and 2023 full year financial results on March 27, 2024. Participants can access the call via phone or webcast, with a replay available for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.67%
Tags
conferences earnings
-
News
GlycoMimetics to Participate in Upcoming Cowen 44th Annual Health Care Conference
Rhea-AI Summary
GlycoMimetics, Inc. (GLYC) CEO to participate in the Leukemia Panel at the Cowen 44th Annual Health Care Conference. The event will be held on March 4, 2024, at 12:50 p.m. ET in Boston, MA. A live webcast and archived recording will be accessible on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.52%
Tags
conferences
News
GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Rhea-AI Summary
GlycoMimetics, Inc. grants a non-qualified stock option award of 130,000 shares to its new Senior Vice President, Technical Operations. The award, given outside the Equity Incentive Plan, is an inducement equity award made as a material inducement for the new employee's acceptance of employment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.47%
Tags
none
-
News
GlycoMimetics Announces Positive Initial Safety and Pharmacokinetic Results from Phase 1a Healthy Volunteer Study of GMI-1687
Rhea-AI Summary
GlycoMimetics, Inc. (GLYC) announces positive initial safety, tolerability, and pharmacokinetic results from a Phase 1a study of GMI-1687, a potential patient-controlled point-of-care treatment for inflammatory diseases, with a focus on sickle cell disease (SCD). The study met its primary and secondary endpoints, with no dose-limiting toxicities or safety signals observed. Subcutaneous dosing achieved target plasma concentrations and linear pharmacokinetics across all dosing levels. Full study results are expected to be presented at an upcoming medical meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.99%
Tags
clinical trial
-
News
GlycoMimetics Announces Independent Presentations on Uproleselan at American Society of Hematology Annual Meeting including New Clinical Data in Treated Secondary Acute Myeloid Leukemia
Rhea-AI Summary
GlycoMimetics, Inc. (Nasdaq: GLYC) announced that the 65th American Society of Hematology Annual Meeting will feature two presentations on uproleselan, a first-in-class E-selectin antagonist for treating secondary Acute Myeloid Leukemia (ts-AML). The Phase 1b/2 trial showed promising results in terms of safety and preliminary efficacy, with an overall response in 39% of patients and reduced bone marrow blasts in 72% of patients. The company is also progressing with a screening trial for pediatric AML patients, indicating a broad potential for uproleselan in different age groups and disease settings.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
News
GlycoMimetics to Participate in Upcoming Jefferies London Healthcare Conference
Rhea-AI Summary
GLYC: GlycoMimetics CEO to Speak at Jefferies London Healthcare Conference on November 16, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.45%
Tags
conferences
-
News
GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2023
Rhea-AI Summary
GlycoMimetics, Inc. reports financial results for Q3 2023, with cash and cash equivalents of $49.4 million as of September 30, 2023. Topline results from the pivotal Phase 3 study of uproleselan in relapsed/refractory Acute Myeloid Leukemia (AML) are on track to be reported by the end of Q2 2024. NDA filing for uproleselan is anticipated by the end of 2024 pending the outcome of the pivotal study. Initial results for GMI-1687 Phase 1a study in sickle cell disease are expected by the end of Q1 2024. Updated independent clinical data on uproleselan will be presented at the American Society of Hematology (ASH) meeting in December.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.65%
Tags
earnings
-
News
GlycoMimetics to Report Third Quarter 2023 Financial Results on November 3, 2023
Rhea-AI Summary
GlycoMimetics to report Q3 2023 financial results
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.08%
Tags
conferences earnings
News
GlycoMimetics Announces First Cohort Dosed in Human Phase 1a Study of GMI-1687
Rhea-AI Summary
GlycoMimetics begins Phase 1a study of GMI-1687 for potential treatment of inflammatory diseases
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.34%
Tags
clinical trial
Stock GLYC logo
GlycoMimetics Inc

Nasdaq:GLYC

GLYC Rankings

#4012 Ranked by Market Cap
#251 Ranked by Stock Gains
N/A Ranked by Dividends

GLYC Stock Data

154.68M
40.31M
3.08%
53.32%
2.47%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Rockville

About GLYC

at glycomimetics, we are committed to helping to make a difference in the lives of people living with sickle cell, cancer, and other serious diseases. our mission is to continue to advance our research and clinical candidates, providing hope for patients as we strive for tomorrow’s breakthrough treatments. glycomimetics is a clinical-stage biotechnology company. we use novel and proprietary glycobiology technology to develop treatments for diseases, particularly where there is high unmet need. since the company’s inception in 2003, we have developed a robust, diversified product pipeline. we are a public company traded on the nasdaq under the symbol glyc.